KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) EPS (Weighted Average and Diluted) (2016 - 2025)

Cme (CME) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $3.24 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 35.0% to $3.24 in Q4 2025 year-over-year; TTM through Dec 2025 was $11.16, a 15.41% increase, with the full-year FY2025 number at $11.16, up 15.41% from a year prior.
  • EPS (Weighted Average and Diluted) was $3.24 for Q4 2025 at Cme, up from $2.49 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.24 in Q4 2025 to a low of $1.42 in Q2 2021.
  • A 5-year average of $2.22 and a median of $2.3 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 124.35% in 2021, then fell 27.52% in 2022.
  • Cme's EPS (Weighted Average and Diluted) stood at $1.69 in 2021, then increased by 4.14% to $1.76 in 2022, then rose by 27.27% to $2.24 in 2023, then rose by 7.14% to $2.4 in 2024, then soared by 35.0% to $3.24 in 2025.
  • Per Business Quant, the three most recent readings for CME's EPS (Weighted Average and Diluted) are $3.24 (Q4 2025), $2.49 (Q3 2025), and $2.81 (Q2 2025).